&lt;p&gt;lncRNAHIF1A-AS2 Promotes Renal Carcinoma Cell Proliferation and Migration via miR-130a-5p/ERBB2 Pathway&lt;/p&gt;

Zhu, Yunxiao; Yang, Ziyi; Chen, Han; Pan, Yang; Gong, Ling; Chen, Falin; Jin, Xiaoxiang; Wen, Shuang; Li, Yi; Chen, Gang

doi:10.2147/ott.s260191

Cited by 9 publications

(6 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…Moreover, miRNA-155 has been acknowledged in cancer drug resistance and as a target for miRNA-based therapy. Several reports have demonstrated that miRNA-130a-5p is aberrantly expressed in various cancers, including lung cancer [ 8 ], gastric carcinoma [ 9 ], and renal carcinoma [ 10 ]. Besides, miRNA-130a-5p can also regulate chemosensitivity, proliferation, and metastasis in tumor cells.…”

Section: Introductionmentioning

confidence: 99%

Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2

Shi

Wang

Zhang

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

Background. Hepatoma is a leading cause of death worldwide, with high metastasis and recurrence rates. The aberrant expression of miRNA-130a-5p is involved in the development and progression of various cancers. However, there are no studies investigating the role of miRNA-130a-5p in hepatoma. The present study is aimed at clarifying the functional role of miRNA-130a-5p in hepatoma progression. Methods. The expression levels of miRNA-130a-5p in hepatoma tissues and cell lines were detected by qRT-PCR assays. Bioinformatic analysis, gain-/loss-of-function experiments, and luciferase activity assays were conducted to verify whether miRNA-130a-5p is targeted by protein tyrosine phosphatase 4A2 (PTP4A2). The functions of miRNA-130a-5p and PTP4A2 in hepatoma were determined by cell proliferation assays. Results. The expression of miRNA-130a-5p was downregulated in hepatoma tissues and was related to poor prognosis. However, the expression level of PTP4A2 was contradictory to that of miRNA-130a-5p, and PTP4A2 upregulation could aggravate hepatoma progression. The ectopic overexpression of PTP4A2 promoted hepatoma cell proliferation in vitro, which could be reversed by miRNA-130a-5p. Conclusions. Our study implies that miRNA-130a-5p, which is downregulated in hepatoma tissues, can suppress hepatoma cell proliferation via targeting PTP4A2.

show abstract

Section: Introductionmentioning

confidence: 99%

Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2

Shi

Wang

Zhang

et al. 2021

Computational and Mathematical Methods in Medicine

View full text Add to dashboard Cite

show abstract

“…Recent studies have also provided more and more evidenced proofs on the important functions of ncRNAs in renal disease or kidney cancers. For example, Shi demonstrated a high expression of lncRNA H19 in the diabetic kidney and in TGF-β2-induced fibrosis in HMVECs, and inhibition of H19 attenuated kidney fibrosis and restored the normal kidney structure (Shi et al, 2020); Zhu suggested that lncRNAHIF1A-AS2 promotes renal carcinoma cell proliferation and migration via the miR-130a-5p/ERBB2 pathway (Zhu et al, 2020); Ai verified that miR-130a-3p facilitates the TGF-β1/Smad pathway in renal tubular epithelial cells and may participate in renal fibrosis by targeting SnoN, which could be a possible strategy for renal fibrosis treatment (Ai et al, 2020). However, the precise mechanism by which LncRNA H19 and miR-130a regulate the AKI process remains unknown, and in vivo studies and clinical data revealing the role of LncRNA H19 and miR-130a in AKI pathogenesis are FIGURE 7 | Potential mechanism elucidating the relationship and interplay of the LncRNA H19/miR-130a/BCL2L11 regulation axis in the human renal proximal tubular cell (HK-2) cellular process under H/R conditions.…”

Section: Discussionmentioning

confidence: 99%

Long Non-coding RNA H19 Augments Hypoxia/Reoxygenation-Induced Renal Tubular Epithelial Cell Apoptosis and Injury by the miR-130a/BCL2L11 Pathway

Yuan

Li²,

Chu

et al. 2021

Front. Physiol.

View full text Add to dashboard Cite

Acute kidney injury (AKI) is a severe kidney disease defined by partial or abrupt loss of renal function. Emerging evidence indicates that non-coding RNAs (ncRNAs), particularly long non-coding RNAs (lncRNAs), function as essential regulators in AKI development. Here we aimed to explore the underlying molecular mechanism of the lncRNA H19/miR-130a axis for the regulation of inflammation, proliferation, and apoptosis in kidney epithelial cells. Human renal proximal tubular cells (HK-2) were induced by hypoxia/reoxygenation to replicate the AKI model in vitro. After treatment, the effects of LncRNA H19 and miR-130a on proliferation and apoptosis of HK-2 cells were investigated by CCK-8 and flow cytometry. Meanwhile, the expressions of LncRNA H19, miR-130a, and inflammatory cytokines were detected by qRT-PCR, western blot, and ELISA assays. The results showed that downregulation of LncRNA H19 could promote cell proliferation, inhibit cell apoptosis, and suppress multiple inflammatory cytokine expressions in HK-2 cells by modulating the miR-130a/BCL2L11 pathway. Taken together, our findings indicated that LncRNA H19 and miR-130a might represent novel therapeutic targets and early diagnostic biomarkers for the treatment of AKI.

show abstract

“…CDKN2B-AS1 overexpression was positively correlated with poor overall survival in RCC patients, and miR-141 expression could also effectively distinguish malignant tissues from non-malignant tissues. Zhu et al [30] found that lncRNA HIF1A-AS2 was highly expressed in renal carcinoma tissues and renal clear cell carcinoma cells. In vivo, HIF1A-AS2 interferes with cell proliferation, invasion and migration, and accelerates cell apoptosis.…”

Section: Discussionmentioning

confidence: 99%

A Risk Assessment Model of Immune-Associated lncRNA to Predict the Prognosis and Immune Landscape of Renal Clear Cell Carcinoma

Zhu

Duan

et al. 2021

Preprint

View full text Add to dashboard Cite

Renal cell carcinoma (RCC) is one of the most common malignancies of the urinary system, accounting for 3% of adult malignancies. Long non-coding RNA (lncRNA) is abnormally regulated in many cancers and can be used as a molecular marker for early diagnosis and prognosis of RCC. Here, original lncRNA datas were retrieved from TCGA, differential co-expression analysis was performed to classify immune-related lncRNA (irlncRNA) with differential expression, and the improved 0 or 1 matrix cyclic single pairing method was used to verify lncRNA pairs. Then, we performed a univariate analysis in combination with an improved Lasso penalty regression that included cross-validation, multiple repetitions, and random stimulus procedures to determine different expression irlncRNA (DEirlncRNA) pairs. AUC values under Receiver Operating Characteristic curve (ROC) were calculated to obtain the optimal model, and AIC values of each point on AUC were calculated to obtain the optimal cut-off point to distinguish the high and low risk groups of Clear-cell renal cell carcinoma (ccRCC) patients. Finally, we evaluated the new model in a variety of clinical settings including survival, clinicopathological features, tumor-infiltrating immune cells, chemotherapy, and checkpoint related biomarkers, all showing promising clinical application.

show abstract

<p>lncRNAHIF1A-AS2 Promotes Renal Carcinoma Cell Proliferation and Migration via miR-130a-5p/ERBB2 Pathway</p>

Cited by 9 publications

References 36 publications

Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2

Downregulated Expression of miRNA-130a-5p Aggravates Hepatoma Progression via Targeting PTP4A2

Long Non-coding RNA H19 Augments Hypoxia/Reoxygenation-Induced Renal Tubular Epithelial Cell Apoptosis and Injury by the miR-130a/BCL2L11 Pathway

A Risk Assessment Model of Immune-Associated lncRNA to Predict the Prognosis and Immune Landscape of Renal Clear Cell Carcinoma

Contact Info

Product

Resources

About